Pre-made Lacnotuzumab benchmark antibody ( Whole mAb, anti-CSF1 therapeutic antibody, Anti-MCSF/CSF-1 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Lacnotuzumab biosimilar, Whole mAb, Anti-CSF1 Antibody: Anti-MCSF/CSF-1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Lacnotuzumab, as known as MCS110, is a novel, high-affinity, humanized, anti-CSF-1 monoclonal antibody that prevents CSF-1 from activating the CSF-1R. The drug is being developed by Novartis Europharm Limited.
| Products Name (INN Index) | Pre-Made Lacnotuzumab biosimilar, Whole mAb, Anti-CSF1 Antibody: Anti-MCSF/CSF-1 therapeutic antibody |
|---|---|
| INN Name | Lacnotuzumab |
| Target | CSF1 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2016 |
| Year Recommended | 2017 |
| Companies | Dana-Farber Cancer Institute,Novartis,Novartis Oncology,Seoul National University Hospital |
| Conditions Approved | NA |
| Conditions Active | Breast cancer,Gastric cancer,Giant cell tumour of tendon sheath,Pigmented villonodular synovitis,Malignant melanoma,Solid tumours |
| Conditions Discontinued | Bone metastases,Prostate cancer |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CSF1 |
| Package |
